Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 329.19M P/E - EPS this Y -7.90% Ern Qtrly Grth -
Income -184.35M Forward P/E -55.93 EPS next Y 73.20% 50D Avg Chg -15.00%
Sales 303.91M PEG -1.22 EPS past 5Y -42.23% 200D Avg Chg -28.00%
Dividend N/A Price/Book 0.88 EPS next 5Y 15.00% 52W High Chg -66.00%
Recommedations 1.70 Quick Ratio 1.38 Shares Outstanding 40.63M 52W Low Chg 3.00%
Insider Own 5.42% ROA -5.82% Shares Float 39.02M Beta 0.65
Inst Own 81.82% ROE -63.15% Shares Shorted/Prior 1.25M/1.39M Price 8.39
Gross Margin 50.90% Profit Margin -60.66% Avg. Volume 370,435 Target Price 13.33
Oper. Margin -12.21% Earnings Date Oct 3 Volume 252,090 Change -2.44%
About AngioDynamics, Inc.

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

AngioDynamics, Inc. News
12/19/24 AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
12/10/24 ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
12/10/24 Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?
12/09/24 NanoKnife gains FDA clearance for prostate tissue ablation
12/09/24 AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
12/03/24 NARI Stock Likely to Gain Following Reimbursement Approval in Japan
11/26/24 STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
11/19/24 NVRO Stock Declines Despite Positive Study Data of Nevro1 System
11/18/24 INBS Stock Declines Despite Positive Results of Pharmacokinetic Study
11/05/24 Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
11/01/24 Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade
10/30/24 GE HealthCare Q3 Earnings Beat Estimates, Sales Meet, Net Margin Up
10/29/24 Investors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 77% over the last three years
10/29/24 AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
10/24/24 AngioDynamics launches long-term study of NanoKnife for prostate cancer
11:32 AM ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
07:00 AM AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
10/22/24 AngioDynamics’ NanoKnife System gains CPT codes for prostate and liver treatments
10/21/24 AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
10/08/24 AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Helsel Dave SVP Global Operation.. SVP Global Operations and R&D Apr 28 Sell 22.44 3,513 78,832 22,874 05/02/22
DONNELLY HOWARD W Director Director Apr 20 Option 15.95 6,022 96,051 104,734 04/21/22
JOHNSON WESLEY Director Director Apr 11 Sell 23.13 7,500 173,475 79,704 04/13/22
Trowbridge Stephen A EVP and CFO EVP and CFO Jan 12 Buy 22.64 1,000 22,640 76,081 01/12/22
Clemmer James C President and CEO President and CEO Jan 11 Buy 22.84 10,000 228,400 390,764 01/12/22
Centea Scott Sr. VP/GM, Global VI.. Sr. VP/GM, Global VIT Oct 15 Option 16.77 12,000 201,240 58,244 10/18/21
Centea Scott Sr. VP/GM, Global VI.. Sr. VP/GM, Global VIT Oct 15 Sell 27.92 12,000 335,040 46,244 10/18/21
Meteny Dennis S Director Director Jul 30 Option 14.64 5,726 83,829 117,865 07/30/21
Trowbridge Stephen A EVP and CFO EVP and CFO Apr 16 Option 14.07 13,625 191,704 73,371 04/16/21
DONNELLY HOWARD W Director Director Apr 05 Option 14.64 5,726 83,829 96,595 04/05/21